Control of Cellular Redox Levels

Abstract

Disclosed herein are compositions and methods for regulating redox status and/or reducing oxidative stress in a subject, the methods and compositions comprising TLR agonists comprising bacterial lysates and/or lysate fractions. Also disclosed are compositions and methods comprising bacterial lysates and/or lysate fractions formulated or administered in combination with one or more other therapeutic or pharmaceutical agents.

1 .- 69 . (canceled) 
     
     
         70 . A bacterial lysate produced according to the method of:
 (a) fermenting a bacterium in a growth medium to the stationary growth phase to produce a fermentation broth;   (b) harvesting bacteria from the fermentation broth;   (c) pasteurizing the harvested bacteria; and   (d) lysing the pasteurized bacteria with a lysozyme to produce the bacterial lysate.   
     
     
         71 .- 112 . (canceled) 
     
     
         113 . The bacterial lysate of  claim 70 , wherein the bacteria are harvested in the mid-logarithmic phase, the late-logarithmic phase, the early stationary phase, the mid-stationary phase, or the late stationary phase. 
     
     
         114 . The bacterial lysate of  claim 70 , wherein the bacterium is a Gram-positive bacterium or a Gram-negative bacterium. 
     
     
         115 . The bacterial lysate of  claim 114 ,
 wherein the Gram-positive bacterium is selected from the group consisting of a bacterium of Lactobacillaceae family, a bacterium of Streptococcaceae family, a bacterium of Bifidobacteriaceae family, and a bacterium of Bacillaceae family; and   wherein the Gram-negative bacterium is selected from the group consisting of a bacterium of  Pseudomonas  genus,  Klebsiella  genus,  Xanthomonas  genus,  Shigella  genus, and  Enterobacter  genus.   
     
     
         116 . The bacterial lysate of  claim 114 ,
 wherein the Gram-positive bacterium is selected from the group consisting of  Bacillus coagulans, Lactobacillus sporogenes, Streptococcus thermophilus, Bifidobacterium animalis, Bifidobacterium animalis,  subspecies  animalis, Bifidobacterium infantis, Bifidobacterium longum, Bifidobacterium breve, Lactobacillus acidophilus, Lactobacillus plantarum, Lactobacillus casei, Lactobacillus delbrueckii, Lactobacillus delbrueckii  subspecies  bulgaricus, Lactococcus lactis, Lactococcus lactis  subspecies  lactis, Streptococcus lactis, Streptococcus thermophilus, Bifidobacterium lactis, Bifidobacterium breve, Pediococcus acidilactici,  and  Lactobacillus helveticus;  and   wherein the Gram-negative bacterium is selected from the group consisting of  Klebsiella oxytocia, Shigella flexneri, Xanthomonas campestris,  and  Pseudomonas flourescens.      
     
     
         117 . The bacterial lysate of  claim 70 , wherein the lysozyme is chicken egg white lysozyme. 
     
     
         118 . The bacterial lysate of  claim 70 , wherein the lysozyme is added to the pasteurized bacteria in suspension to a final concentration of about 0.5%, or about 1%, or about 2%, or about 3%, or about 4% by volume. 
     
     
         119 . The bacterial lysate of  claim 70 , wherein step (d) comprises treatment of the pasteurized bacteria with lysozyme from about 6 hours to about 10 hours. 
     
     
         120 . The bacterial lysate of  claim 70 , wherein step (d) is performed at from about 35° C. to about 45° C.